Skip to main content
. 2023 Jul 24;29(8):2110–2120. doi: 10.1038/s41591-023-02478-2

Extended Data Fig. 3. Waterfall plot of the best change from baseline in target lesions according to the best objective response of patients from cohort 2 in FAS population (n = 72) according to HER2 status.

Extended Data Fig. 3

On the left, patients with HER2 IHC 1+ (n = 41) and on the right patients with HER2 IHC 2 + /ERBB2 ISH- (n = 31) treated with T-DXd.